Skip to content

Clinical observational study on the treatment of ovarian cancer by combination of traditional Chinese and Western medicine(Single center controlled prospective cohort study)

Clinical observational study on the treatment of ovarian cancer by combination of traditional Chinese and Western medicine(Single center controlled prospective cohort study)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2025000437
Enrollment
Unknown
Registered
2025-02-27
Start date
2024-05-01
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

Western medicine therapy group:Chemotherapy
Integrated traditional Chinese and Western medicine therapy group:Traditional Chinese medicine combined with chemotherapy

Sponsors

Jiangsu Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-80; 2) Meet the diagnostic criteria for ovarian cancer in the Ovarian Cancer Diagnosis and Treatment Guidelines (2022 edition); 3) ECOG score: 0~2; 4) Expected survival =12 weeks; 5) The function of vital organs meets the following requirements (no blood component cell growth factor correction therapy drugs are allowed within 14 days before randomization) : neutrophil absolute count =1.5×10^9/L; Platelet =90×10^9/L; Hemoglobin =90 g/L; Serum albumin =30 g/L; Bilirubin =1.5× ULN; ALT and AST =3 x ULN; In the presence of liver metastasis ALT and AST were <5 ×ULN. Serum creatinine =1.5×ULN; 6) Informed consent voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1) No pathological diagnosis; 2) have serious primary heart liver lung kidney blood or serious diseases affecting their survival; 3) Unable to give fully informed consent; 4) Other situations that are not suitable for inclusion according to the researcher's judgment such as changes in the working environment and other volatile interviewees; 5) Patients who are participating in other clinical studies.

Design outcomes

Primary

MeasureTime frame
Quality of life score of cancer patients;Progression-Free-Survival;

Secondary

MeasureTime frame
Overall survival;Duration of remission;Response Evaluation Criteria in Solid Tumors;Assessment of female fertility;

Countries

China

Contacts

Public ContactCheng Wenjun

Jiangsu Province Hospital

chengwenjun@jsph.org.cn+86 132 1802 1531

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026